Affimed N.V. (AFMD) Analysts See $-0.19 EPS

March 14, 2018 - By Ellis Scott

 Affimed N.V. (AFMD) Analysts See $ 0.19 EPS

Analysts expect Affimed N.V. (NASDAQ:AFMD) to report $-0.19 EPS on March, 29.They anticipate $0.02 EPS change or 11.76 % from last quarter’s $-0.17 EPS. After having $-0.21 EPS previously, Affimed N.V.’s analysts see -9.52 % EPS growth. It closed at $2.2 lastly. It is down 19.09% since March 15, 2017 and is downtrending. It has underperformed by 35.79% the S&P500.

Affimed N.V. (NASDAQ:AFMD) Ratings Coverage

Among 8 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Affimed Therapeutics had 17 analyst reports since August 6, 2015 according to SRatingsIntel. The stock has “Hold” rating by Jefferies on Wednesday, September 9. The rating was initiated by BMO Capital Markets with “Outperform” on Tuesday, April 12. Laidlaw initiated the shares of AFMD in report on Thursday, December 10 with “Buy” rating. Oppenheimer maintained it with “Buy” rating and $700 target in Tuesday, August 1 report. The stock of Affimed N.V. (NASDAQ:AFMD) earned “Hold” rating by Zacks on Thursday, September 3. The firm earned “Hold” rating on Monday, June 12 by Jefferies. The stock has “Hold” rating by Jefferies on Thursday, May 19. The rating was initiated by Wells Fargo with “Outperform” on Friday, December 4. The firm has “Sell” rating by Zacks given on Monday, August 10. Oppenheimer maintained Affimed N.V. (NASDAQ:AFMD) rating on Thursday, August 6. Oppenheimer has “Outperform” rating and $19 target.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. The company has market cap of $133.46 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. It currently has negative earnings. The company's product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

More important recent Affimed N.V. (NASDAQ:AFMD) news were published by: which released: “What’s Happening with These Biotech Stocks? — Aeterna Zentaris, Affimed …” on March 13, 2018, also published article titled: “Affimed Announces Pricing of Public Offering of Common Stock”, published: “Affimed Announces Fourth Quarter and Year End 2017 Financial Results and …” on March 13, 2018. More interesting news about Affimed N.V. (NASDAQ:AFMD) was released by: and their article: “Affimed to Present at the Cowen and Company 38th Annual Health Care Conference” with publication date: March 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: